The first sequential clinical study of the Austrian strain vaccine was launched, two points should be noted
arts/
On May 9, the sequential clinical trial of the COVID-19 virus inactivated vaccine of the Omicoron strain (hereinafter referred to as the Austrian strain) of Sinopharm China Bio-Beijing Institute of Biological Products was launched in Hunan Province. This is the first time that a sequential clinical study of the Austrian-strain COVID-19 vaccine has been carried out among people who have been vaccinated against COVID-19 after the China Bio-Austria COVID-19 vaccine started blank population vaccination in Hangzhou, Zhejiang Province on May 1.
According to the "Global Times" reporter, this is the world's first comprehensively designed sequential clinical trial of an inactivated vaccine against the Austrian strain of COVID-19 virus. Conduct clinical trials. The study will evaluate the safety and immunogenicity of the vaccine in humans. The relevant clinical program needs to be further discussed with experts and drug regulatory authorities, and it is expected to take about 3-4 months to complete.
First of all, we need support for this matter that benefits the country and the people . Secondly, we have also seen some problems in American society, that is, in the name of the American people, pharmaceutical companies have implemented various compulsory vaccinations, which has led to the destruction of some legal systems in American society in the past, such as voluntary vaccination and other related laws. I believe that our country has always put the people first, and there will definitely not be a situation of compulsory vaccination like the United States.
Especially in the stage of clinical trials, this trial is actually a very complicated process, and it should be a very careful process. I believe that the experts from Sinopharm China Bio-Beijing Institute of Biological Products have systematically considered that the development of this vaccine in the past usually takes 10-30 years. The core reason is to find out the side effects of clinical follow-up after vaccination. , this requires long-term tracking to understand.
Therefore, it is still recommended: 1. Is it convenient to publish the clinical follow-up research report on the side effects of previous vaccinations? After all, it is a drug, and the common people should still have the right to know. 2. Whether we can fully give everyone the right to choose freely in the process of this clinical test, after all, it is a test drug.
The last thought, the United States is now beginning to reflect on the side effects of vaccination and the harm it brings to the human body. Some medical experts have begun to think about a problem, and they do not know whether they are thinking correctly. Because after all, they are only medical experts in the United States, and the science and technology of medicine and vaccines in the United States are completely inferior to ours. They do not understand science, so I propose to discuss with you today:
Even if this vaccine is administered one by one, the body's immune system will become fatigued, and the constant stimulation of the drug will, to a certain extent, accelerate the over-fatigue and aging of the immune system, and of course resistance may occur. More importantly, if vaccination fails to produce an effective immune response, the next possible hidden danger is the reverse antibody enhancement-dependent effect. It is unknown whether this problem can be discovered through clinical research.